← Opus Genetics, Inc. (IRD) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Opus Genetics, Inc. (IRD)
Pharmaceutical Preparations · market cap $398M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
1
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Opus Genetics (IRD) is an 18-person gene therapy company with a $330M market cap focused on inherited retinal diseases. Its lead asset, AAV8.hLCA5, is in Phase 2 for Leber Congenital Amaurosis type 5 (LCA5), a rare blinding pediatric disease. A PDUFA date for OPX-102 on 2027-01-20 represents the near-term binary catalyst of highest importance.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2027-01-20PDUFA · OPX-102imp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AAV8.hLCA5 | Phase 2 | LCA5 |
Price & technical context
3-month
+6.6%
6-month
-3.8%
12-month
+173.3%
52-wk range
$1.74–$6.07
vs 50-day MA
+4.8%
vs 200-day MA
+13.5%
Realized vol
78.3%
Max drawdown
-51.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IRD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.